Outsourcing already offers unique services to big pharma and biotech companies, but AMRI ($AMRI) wants to put a different spin on what it can offer. By launching what it calls SmartSourcing, the Albany CRMO hopes to provide clients with insourcing and outsourcing opportunities that lead to high-quality performance and scientific expertise without breaking the bank.
As more pharma companies turn to their outsourcing partners to fill the need for research, SmartSourcing is meant for clients to tap into AMRI's people, knowledge, facilities, expertise and global project management, according to an AMRI release. In turn, AMRI can provide exactly what is needed across the discovery, development and manufacturing processes.
While we immediately associate contract research and manufacturing with outsourcing, an industry trend is emerging that encourages insourcing. It is something with which AMRI already has experience. One notable example is its work with Eli Lilly ($LLY), which brought on 40 AMRI researchers to work in-house using laboratory space left vacant by downsizing. Rather than outsource work thousands of miles away to China, Eli Lilly went to AMRI, and the two entities could communicate the without the annoyance of different time zones, as FierceCRO reported last month.
"Pharma companies are looking for more supplier accountability, greater trust and consultation," remarked AMRI president and CEO Thomas E. D'Ambra in a statement. "They want a better balance of risk, but also greater flexibility and tailored business models that address their unique needs."
- read the release